Details of the Active Pharmaceutical Ingredient (API)

General Information of API (ID: D00001)
Name
Dalfampridine
Synonyms    Click to Show/Hide the Synonyms of This API
4-aminopyridine; 504-24-5; pyridin-4-amine; Fampridine; 4-Pyridinamine; Dalfampridine; 4-Pyridylamine; p-Aminopyridine; Avitrol; gamma-Aminopyridine; Ampyra; Avitrol 200; Pyridine, 4-amino-; Amino-4 pyridine; Pimadin (free base); Compound 1861; Phillips 1861; FAMPYRA; Neurelan; Prc 1237; VMI 10-3; C5H6N2; 4-amino-pyridine; UNII-BH3B64OKL9; 4- Aminopyridine; pyridin-4-ylamine; EL-970; NSC 15041; .gamma.-Aminopyridine; 4-AMINOPYRDINE; N07XX07; 4-Aminopyridine, 98%; MFCD00006439; BH3B64OKL9; MLS000069400; CHEMBL284348; Dalfampridine (4-aminopyridine); CHEBI:34385; NSC-15041; NCGC00015009-08; SMR000058211; 4 Aminopyridine; Fampridine-SR; DSSTox_CID_3870; DSSTox_RID_77212; DSSTox_GSID_23870; Caswell No. 038; VMI-103; Mi-W-3; CAS-504-24-5; Ampyra (TN); HSDB 6037; VMI 103; SR-01000075299; EINECS 207-987-9; RCRA waste no. P008; EPA Pesticide Chemical Code 069201; Dalfampridine [USAN:INN]; BRN 0105782; fampridina; fampridinum; Frampridine; Ampydin; BIIB041; Pymadin; AI3-52547; BIIB 041; Fampridine-PR; Dalfampridine-ER; 4-pyridyl amine; para-aminopyridine; 4-amino pyridine; pyridine-4-amine; Neurelan (TN); pyridine-4-ylamine; Fampridine [INN]; Fampyra (TN); pyridin-4-yl-amine; 4-Aminopyridine 10; PubChem1281; Philips 1861; Dalfampridine (USAN); Spectrum_000155; Tocris-0940; Fampridine (JAN/INN); PYRIDINE,4-AMINO; Opera_ID_1768; Spectrum2_001413; Spectrum3_000914; Spectrum4_001013; Spectrum5_001501; Lopac-A-0152; UPCMLD-DP125; WLN: T6NJ DZ; 4-Aminopyridine (4-AP); 4-Aminopyridine, >=99%; Lopac0_000032; BSPBio_001562; KBioGR_000282; KBioGR_001505; KBioSS_000282; KBioSS_000635; 4-imino-1,4-dihydropyridine; 5-22-09-00106 (Beilstein Handbook Reference); ARONIS25052; DivK1c_000572; SPECTRUM1501130; SPBio_001486; BIIB-041; GTPL2416; CL-COB-III-274-1; DTXSID0023870; UPCMLD-DP125:001; AMPD00207; BDBM10458; HMS501M14; KBio1_000572; KBio2_000282; KBio2_000635; KBio2_002850; KBio2_003203; KBio2_005418; KBio2_005771; KBio3_000563; KBio3_000564; KBio3_001888; NINDS_000572; Bio1_000353; Bio1_000842; Bio1_001331; Bio2_000282; Bio2_000762; HMS1361O04; HMS1791O04; HMS1921H15; HMS1989O04; HMS2092F05; HMS2234N24; HMS3260G05; HMS3267E21; HMS3370J03; HMS3402O04; HMS3414H15; HMS3678H13; HMS3886I09; KUC111877N; Pharmakon1600-01501130; ZINC599985; ACT05167; HY-B0604; NSC15041; VMI-10-3; Tox21_110065; Tox21_200793; Tox21_500032; ANW-75388; BBL009925; CCG-39031; HTS004685; NSC757845; RB8003; RW2023; SBB004393; STK298717; AKOS000119896; Tox21_110065_1; BS-3729; DB06637; LP00032; LS20499; MCULE-6604546217; NSC-757845; QC-4324; SDCCGMLS-0066228.P001; SDCCGSBI-0050021.P004; VP10051; IDI1_000572; IDI1_034032; p-Aminopyridine [UN2671] [Poison]; NCGC00015009-01; NCGC00015009-02; NCGC00015009-03; NCGC00015009-04; NCGC00015009-05; NCGC00015009-06; NCGC00015009-07; NCGC00015009-09; NCGC00015009-10; NCGC00015009-11; NCGC00015009-12; NCGC00015009-13; NCGC00015009-14; NCGC00015009-16; NCGC00015009-23; NCGC00015009-24; NCGC00024890-01; NCGC00024890-02; NCGC00024890-03; NCGC00024890-04; NCGC00024890-05; NCGC00024890-06; NCGC00024890-07; NCGC00024890-08; NCGC00024890-09; NCGC00024890-10; NCGC00258347-01; NCGC00260717-01; BP-21343; SBI-0050021.P003; DB-028705; AM20061261; EU-0100032; FT-0665455; ST45053817; AZ0001-0464; A 0152; C13728; D04127; M-6065; 68146-EP2269990A1; 68146-EP2284157A1; 68146-EP2289894A2; 68146-EP2298731A1; 68146-EP2308874A1; 68146-EP2380872A1; 79676-EP2305695A2; 79676-EP2305696A2; 79676-EP2305697A2; 79676-EP2305698A2; AB00052209_12; [J.Pharmacol.Exp.Ther. 275:864 (1995)]; AC-907/25014071; Q372539; 4-Aminopyridine, PESTANAL(R), analytical standard; Q-200436; SR-01000075299-1; SR-01000075299-3; SR-01000075299-5; F2190-0487; Z955123498; METHYL3,5-DIBROMO-2,4-DIHYDROXY-6-METHYLBENZOATE; Dalfampridine, United States Pharmacopeia (USP) Reference Standard
Clinical Status
Approved
Disease Indication Multiple sclerosis ICD-11: 8A40 [1]
PubChem CID
1727
Formula
C5H6N2
Canonical SMILES
C1=CN=CC=C1N
InChI
1S/C5H6N2/c6-5-1-3-7-4-2-5/h1-4H,(H2,6,7)
InChIKey
NUKYPUAOHBNCPY-UHFFFAOYSA-N
   Click to Show/Hide the Molecular Data (Structure/Property) of This API
Structure
<iframe style="width: 300px; height: 300px;" frameborder="0" src="https://embed.molview.org/v1/?mode=balls&cid=1727"></iframe>
3D MOL 2D MOL
Physicochemical Properties Molecular Weight 94.11 Topological Polar Surface Area 38.9
XlogP 0.3 Complexity 48
Heavy Atom Count 7 Rotatable Bond Count 0
Hydrogen Bond Donor Count 1 Hydrogen Bond Acceptor Count 2
Full List of Drug Formulations (DFMs) Containing This API
          Dalfampridine 10 mg tablet Click to Show/Hide the Full List of Formulation(s):          1 Formulation(s)
             Drug Formulation 1 DFM Info click to show the detail info of this DFM
                   All DIGs    Click to Show/Hide the Full List of DIGs in This DFM
Magnesium stearate; Titanium dioxide; Silicon dioxide; Cellulose, microcrystalline; Hypromelloses; Polyethylene glycols
                   Dosage Form 12 HR Extended Release Oral Tablet
                   Company Acorda Therapeutics
                   DIG(s) with
                   Biological Activity
DIG Name DIG Info Representative Biological Activity of This DIG REF
Magnesium stearate DIG Info Albendazole monooxygenase (Protein expression downregulation) [2]
Silicon dioxide DIG Info Albendazole monooxygenase (Protein expression downregulation) [2]
References
1 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5.
2 Effects of commonly used excipients on the expression of CYP3A4 in colon and liver cells. Pharm Res. 2010 Aug;27(8):1703-12.

If you find any error in data or bug in web service, please kindly report it to Dr. Zhang and Dr. Mou.